3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Thoracic
3
Dermatologic
3
Gynecologic
2
Genitourinary
2
CNS
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
118
Myelodysplastic Syndromes
37
Hodgkin Disease
35
Leukemia, Myeloid, Acute
33
Lymphoma
31
Lymphoma, Non-Hodgkin
30
Neoplasms, Plasma Cell
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Leukemia
26
Leukemia, Lymphocytic, Chronic, B-Cell
23
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
22
Myeloproliferative Disorders
19
Hematologic Neoplasms
18
Primary Myelofibrosis
17
Recurrence
12
Anemia, Aplastic
12
Lymphoma, Follicular
11
Lymphoma, Mantle-Cell
10
Graft vs Host Disease
10
Lymphoma, B-Cell, Marginal Zone
9
Hematologic Diseases
9
Burkitt Lymphoma
9
Leukemia, Prolymphocytic
8
Leukemia, Plasma Cell
8
Leukemia, Myelomonocytic, Chronic
8
Anemia, Refractory, with Excess of Blasts
6
Polycythemia Vera
4
Ovarian Neoplasms
4
Lymphoma, B-Cell
4
Waldenstrom Macroglobulinemia
3
Interventions
saracatinib
1
fludarabine
1
cediranib
1
Temozolomide
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Molecular Diagnostic Techniques
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Cyclophosphamide
1
Cannabidiol
1
Bortezomib
1
Biological Therapy
1
Bevacizumab
1
Bariatric Surgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
fludarabine
×
Plasma cell
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled